Unmet Need in Essential Thrombocythemia and Polycythemia Vera

被引：3
|
作者：
Kishtagari, Ashwin [1 ]
Gerds, Aaron T. [1 ]
机构：
[1] Cleveland Clin, Leukemia & Myeloid Disorders Program, Taussig Canc Inst, 9500 Euclid Ave,CA60, Cleveland, OH 44120 USA
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2021年 / 35卷 / 02期
关键词：
Myeloproliferative neoplasms; MPN; ET; PV; Bomedemstat; IFN-alpha; Idasanutlin; Givinostat;
D O I：
10.1016/j.hoc.2021.01.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Consensus guidelines have helped to standardize the care of patients with essential thrombocythemia and polycythemia vera, focusing on reducing the risk of thrombosis, mitigating symptoms, and avoiding therapies that may accelerate disease progression. However, many unmet needs still exist ranging from the roll of antiplatelet therapy in ET to medications that reduce disease progression. Retrospective studies suggest an improvement in myelofibrosis-free survival for treatment with interferons; new agents are looking to also enact disease modification. © 2021 Elsevier Inc.
引用
收藏
页码：295 / 303
页数：9
相关论文
共 50 条
  • [21] THROMBOEMBOLISM PREDICTIVE FACTORS IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
    Bellora, A.
    Tamiazzo, S.
    Primon, V.
    Pini, M.
    Corsetti, M. T.
    Cornaglia, E.
    Demichelis, M.
    Santi, R.
    Contino, L.
    Levis, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 410 - 410
  • [22] Interferon-α therapy in polycythemia vera and essential thrombocythemia
    Elliott, MA
    Tefferi, A
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1997, 23 (05): : 463 - 472
  • [23] RESULTS of Allogeneic TRANSPLANTATION for Polycythemia VERA and Essential Thrombocythemia
    Ballen, Karen K.
    Arora, Mukta
    Zhu, Xiaochun
    Agovi, Manza
    Kalaycio, Matt
    Maziarz, Richard T.
    Cortes, Jorge E.
    Woolfrey, Ann
    Horowitz, Mary M.
    Saber, Wael
    BLOOD, 2010, 116 (21) : 1444 - 1445
  • [24] Treatment of polycythemia vera and essential thrombocythemia: The role of Pipobroman
    Passamonti, F
    Lazzarino, M
    LEUKEMIA & LYMPHOMA, 2003, 44 (09) : 1483 - 1488
  • [25] Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera
    Reikvam, H.
    Tiu, R. V.
    LEUKEMIA, 2012, 26 (04) : 563 - 571
  • [26] Emerging agents and regimens for polycythemia vera and essential thrombocythemia
    Rory M. Shallis
    Nikolai A. Podoltsev
    Biomarker Research, 9
  • [27] Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia
    Johansson, P
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (03): : 171 - 173
  • [28] Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice
    Tefferi, Ayalew
    Barbui, Tiziano
    MAYO CLINIC PROCEEDINGS, 2015, 90 (09) : 1283 - 1293
  • [29] Platelet activation and inhibition in polycythemia vera and essential thrombocythemia
    Patrono, Carlo
    Rocca, Bianca
    De Stefano, Valerio
    BLOOD, 2013, 121 (10) : 1701 - 1711
  • [30] Acute coronary disease in essential thrombocythemia and polycythemia vera
    Rossi, C
    Randi, ML
    Zerbinati, P
    Rinaldi, V
    Girolami, A
    JOURNAL OF INTERNAL MEDICINE, 1998, 244 (01) : 49 - 53
12345